Emblation Announces Commercial Partnership with Saorsa Inc

Emblation is pleased to announce an exclusive commercial partnership in the US with Saorsa Inc, for the distribution of the Swift® microwave system.

The Swift® system is a surface-based device intended for the coagulation of soft tissue during non-invasive procedures, and received 510(k) clearance in October 2018.

Emblation's Director of Strategy & Marketing, Jonathan Williamson, commented: "We're excited to partner with Saorsa to introduce the Swift® treatment to the US. We believe the best way to reach more patients globally is by working with carefully chosen partners who share our passion for the fields of medicine we work in, and our vision and commitment to continuous clinical improvements, efficient, patient-friendly treatments, and technology solutions that can have a tangible impact on clinics.

The Saorsa management team have an extensive and impressive record of success in the launch and growth of innovative medical technology, both in the US and globally, and we look forward to working closely together to deliver Swift® to patients across the US."

For all US enquiries, please visit esaorsa.com. For enquiries in other countries, please visit our distributors page.

About Emblation

Emblation is a global leader in medical microwave technology, with a focus on radical innovation in the treatment of HPV infections, dermatology, cardiology, and oncology.

Established in the USA in 2007, the company relocated to Scotland the following year to continue research into novel microwave ablation products. The team is led by some of the world's foremost medical microwave experts, with a wealth of experience in the design, development and manufacture of microwave applications for a range of medical fields. Emblation is committed to providing next generation solutions for today's medical conditions.